Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook

Jean-Frederic Viret, Ph.D. Promoted to Vice President and Chief Financial

Officer; Richard P. Powers to Transition to Consultant Role

SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported 2007 fourth quarter and year-end financial results and accomplishments and outlined its objectives for 2008 based on commercialization plans for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate.

"We are preparing on multiple fronts for a successful commercial introduction for Zingo in the second quarter by driving product demand through multiple initiatives and direct contact with our target customers," said John P. McLaughlin, chief executive officer of Anesiva. "We also have a very active clinical program with Adlea that includes two ongoing Phase 2 trials in post-surgical pain as well as plans to advance into two Phase 3 registration trials in post-surgical indications in the first half of 2008."

Recent Highlights and Accomplishments

Anesiva continued to execute on its corporate, commercial and clinical milestones in late 2007 and early 2008:


-- Hired sales force of 15 regional account managers (RAMs) and two

directors targeting key pediatric hospitals to commercialize Zingo for

the approved patient population (three to 18 years of age). The RAMs

completed training and went into their territories at the end of

January. The Anesiva sales force will focus their efforts on creating

demand by educating nurses and physicians on the importance of treating

I.V. pain and on the features and use of Zingo for their pediatric

patients. These initiatives will be complemented by Zingo co-promotion

and distribution partner Sagent Pharmaceuticals' representatives, who

will work primarily with hospital pharmacies.

-- Launched two initiatives aimed to improve peripheral venous access pain

management in children: RN VOICE (Registered Nurses for Venipuncture

Optimization through Increased Comfort and Education), a

multidisciplinary group of healthcare professionals led by nurses to

facilitate better management of venous access pain; and, an interactive Web site designed for

parents and healthcare providers seeking to better manage peripheral

venous access pain in children.

-- Proceeded with plans to file a supplemental New Drug Application with

the FDA in the first quarter of 2008 to expand the Zingo label to

include adults, based on successful pivotal Phase 3 trial in

approximately 700 adult patients.

-- Signed exclusive license agreement with Sigma-Tau SpA for the marketing

and distribution of Zingo in six European countries: Italy, France,

Germany, Netherlands, Belgium and Luxembourg. Sigma-Tau will oversee

all necessary regulatory filings, and will be responsible for all

marketing and sales of Zingo in their territory.

-- Granted an exclusive license to Medical Futures, Inc. for the marketing

and distribution of Zingo in Canada. Under the terms of the license,

Medical Futures will be responsible for all regulatory filings,

marketing, distribution and sales in Canada.

-- Conducted webcast and briefing in New York City with financial analysts

and major investors to present plans for the commercial introduction of



-- Continued enrollment in two Phase 2 trials of Adlea for post-operative

pain associated with orthopedic surgeries: one in patients undergoing

total hip replacement surgery, and a second in patients undergoing knee

replacement surgery. These trials are investigating a higher dose of

Adlea that might provide increased efficacy. Anesiva previously

successfully studied a lower dose of Adlea in patients undergoing knee

replacement surgery.

-- Proceeded with plans to initiate Phase 3 trials of Adlea in

post-surgical pain associated with orthopedic surgeries, including one

trial in patients undergoing bunionectomy surgeries and one trial in

patients undergoing total knee replacement surgeries.

Corporate Developments

Anesiva announced that Richard P. Powers, vice president and chief financial officer, will resign at the end of the month to pursue other interests, while remaining a consultant to the company. He will be succeeded by Jean-Frederic Viret, Ph.D., who is currently Anesiva's vice president, finance.

"Dick has been a valuable member of the Anesiva senior management team, having served as chief financial officer and leader of successful financing efforts almost since the company's inception. We are grateful for his many contributions and will appreciate the ongoing benefit of his counsel," said Mr. McLaughlin. "We are also pleased that we will have a smooth transition with the promotion of Jean Viret to vice president and chief financial officer. Jean has been a leader in our finance group since 2002, and we are confident that in this new position he will have a significant role in Anesiva's growth."

Jean-Frederic Viret, Ph.D. joined Anesiva in 2002 and was promoted to vice president, finance in 2006. Prior to Anesiva, Jean was associate director of finance at Tularik Inc. (now Amgen) from 2000 to 2002. He served as a senior associate with PricewaterhouseCoopers from 1997 to 2000. Dr. Viret holds an M.B.A. from the Johnson School at Cornell University, and a Ph.D. in molecular biology from the Universite Louis Pasteur. He completed a postdoctoral fellowship in molecular biology at the Massachusetts Institute of Technology and was a visiting fellow in molecular biology at Harvard University. Dr. Viret is also a certified public accountant.

Additional developments include:

-- Appointed Daniel S. Janney, a managing director of Alta Partners, a

venture capital firm investing in life sciences and information

technology companies, to the Anesiva board of directors.

- Completed successful public offering of common stock in December,

raising net proceeds of approximately $47.7 million.

Fourth Quarter and Fiscal Year 2007 Financial Results

Total operating expenses in the fourth quarter of 2007 were $18.1 million, including $1.7 million of non-cash stock-based compensation, compared to total operating expenses of $16.2 million, including $2.3 million of non-cash stock-based compensation, in the fourth quarter of 2006. For the year ended December 31, 2007, operating expenses were $61.5 million compared to $58.8 million for the year ended December 31, 2006.

Operating expenses during the quarter primarily related to the continued development and commercial preparations to launch the company's lead product candidate, Zingo, a fast-acting, needle-free, local anesthetic. Additional operating expenses related to the ongoing development of Adlea, which has been shown in numerous clinical studies to provide site-specific, moderate-to-severe pain relief for weeks to months following a single application.

For the fourth quarter of 2007, Anesiva's net loss was $17.7 million, or $0.60 per share. In the fourth quarter of 2006, the net loss was $15.3 million, or $0.65 per share. The net loss for the year ended December 31, 2007 was $59.4 million, or $2.12 per share, and for the year ended December 31, 2006, the net loss was $55.6 million, or $2.69 per share.

As of December 31, 2007, cash, cash equivalents and investments were $90.8 million compared to $54.5 million at September 30, 2007. Anesiva completed a public offering of 12.3 million shares of its common stock in December 2007. The net proceeds, after deducting underwriting discounts and offering expenses, were approximately $47.7 million. Common shares issued and outstanding totaled approximately 40.4 million at December 31, 2007.

2008 Outlook

With the $47.7 million in net proceeds from the December 2007 common stock offering and $90.8 million in cash, cash equivalents and investments as of December 31, 2007, the company has sufficient resources to fund anticipated expenses for all of 2008 and into 2009. Anesiva plans to update this guidance, including estimated 2008 operating expenses, going forward. The company also plans to provide projections related to Zingo sales in the second half of 2008
In 2008, Anesiva anticipates accomplishing the following milestones:

-- File a supplemental New Drug Application for Zingo in the first quarter

of 2008 to expand the label to include adults;

-- Continue manufacturing preparations to support commercial introduction

of Zingo in the second quarter of 2008;

-- Initiate a Phase 3 trial evaluating Adlea in bunionectomy surgeries,

expected to occur imminently;

-- Initiate a Phase 3 trial evaluating Adlea in total knee replacement

surgeries in the first half of 2008;

-- Initiate additional Phase 2 trials in 2008 evaluating Adlea in

osteoarthritis of the knee and in arthroscopic shoulder surgeries;

-- Report data from Phase 2 trial of Adlea in total knee replacement

surgeries and Phase 3 trial in bunionectomy surgeries;

In addition, Anesiva is pursuing corporate partnerships for the registration and commercialization of Zingo outside the licensed territories, and in support of the development and commercialization of Adlea for multiple potential indications.

Conference Call Details

Anesiva will conduct a webcast conference call with the investment community at 4:30 p.m. EDT, today, February 11, 2008 to discuss its financial results and to review the company's progress and future outlook. Interested parties can listen to the live conference call by dialing 800-340-6289 (international dial: 706-634-1538) or by logging on to and going to the Investor Information page. For those unable to participate via the Internet, a replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 31729950. The webcast will be available until the company's next quarterly financial results conference call.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms, whether Anesiva can secure FDA approval for the use of Zingo in adults, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended September 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Anesiva, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three months ended Twelve months ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited) (unaudited) (Note)

Contract revenue $ 1 $ 89 $ 51 $ 89

Operating expenses:

Research and

development 10,745 9,810 35,660 35,259

General and

administrative 7,296 6,366 25,722 23,582

Total operating

expenses 18,041 16,176 61,382 58,841

Loss from operations (18,040) (16,087) (61,331) (58,752)

Interest and other

income (expense), net 331 772 2,049 3,185

Net loss $(17,709) $ (15,315) $(59,282) $(55,567)

Basic and diluted net

loss per common share $ (0.60) $ (0.65) $ (2.12) $ (2.69)

Shares used to compute

basic and diluted net

loss per common share 29,713 23,393 28,024 20,643


compensation $ 1,694 $ 2,259

Anesiva, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

December 31, December 31,

2007 2006

(unaudited) (Note)


Cash, cash equivalents

and short-term investments $90,840 $85,055

Other current assets 2,225 1,153

Total current assets 93,065 86,208

Property and equipment, net 15,276 8,446

Other assets, non-current 1,395 722

Total assets $109,736 $95,376

Liabilities and stockholders'


Current liabilities $12,175 $6,831

Long term obligations 9,047 217

Total stockholders' equity 88,514 88,328

Total liabilities and

stockholders' equity $109,736 $95,376

(Note): Derived from audited financial statements at that date.

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
Breaking Biology News(10 mins):